Major Depressive Disorder ↔ psilocybin

Relations (1)

related 6.00 — strongly supporting 6 facts

Psilocybin is being investigated as a therapeutic intervention for Major Depressive Disorder, as evidenced by clinical trials comparing its efficacy to conventional treatments {fact:1, fact:2} and individual patient experiences [1]. Research protocols and studies further explore the procedural administration [2] and the resulting cognitive, neural, and neurochemical changes in patients with this condition {fact:5, fact:6}.

Facts (6)

Sources

Neuroimaging in psychedelic drug development: past, present, and ... nature.com Nature 2 facts

claimAn open-label study of patients with major depressive disorder found that psilocybin treatment led to increased cognitive flexibility (measured by perseverative errors on a set-shifting task) and neural flexibility (measured by functional connectivity via fMRI) that persisted for up to four weeks post-treatment.

measurementAn open-label study of patients with major depressive disorder reported reductions in glutamate and N-Acetylaspartate concentrations in the anterior cingulate cortex, as measured by Magnetic Resonance Spectroscopy (MRS), following psilocybin treatment.

History and Current Status of Psychedelics and Entactogens ... - NCBI ncbi.nlm.nih.gov Stroud C, Posey Norris SM, Matney C · National Academies Press 2 facts

accountNora Osowski participated in a clinical trial for psilocybin to treat major depressive disorder at Johns Hopkins University after failing to find relief with conventional antidepressants.

procedureThe psilocybin clinical trial protocol at Johns Hopkins University for major depressive disorder includes preparatory visits with a facilitator, treatment sessions involving eyeshades and headphones with standardized music, and subsequent integrative sessions to process insights.

Published Studies — Johns Hopkins Center for Psychedelic and ... hopkinspsychedelic.org Johns Hopkins Center for Psychedelic and Consciousness Research 2 facts

referenceA 2024 study published in eClinicalMedicine by Buyukbabani et al. examined the effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder, utilizing an observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial.

referenceA 2023 study published in 'JAMA' evaluated the efficacy of single-dose psilocybin treatment for major depressive disorder.